Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma
暂无分享,去创建一个
Feng Zhang | Zhenqing Feng | Jin Zhu | Q. Tang | Jianfei Huang | Feng Zhang | Xia-ling Zhang | Yu-hua Li
[1] C. Gahan,et al. Current status and future perspectives , 2011 .
[2] A. Jemal,et al. Global Cancer Statistics , 2011 .
[3] Zhenqing Feng,et al. A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes , 2010, Cytotechnology.
[4] M. Yeh,et al. TGF‐β inactivation and TGF‐α overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer , 2009, International journal of cancer.
[5] X. Wang,et al. Cooperation of tumor‐derived HBx mutants and p53‐249ser mutant in regulating cell proliferation, anchorage‐independent growth and aneuploidy in a telomerase‐immortalized normal human hepatocyte‐derived cell line , 2009, International journal of cancer.
[6] Zhenqing Feng,et al. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. , 2009, Human pathology.
[7] Jin-Lin Hou,et al. Hepatocellular carcinoma in the Asia pacific region , 2009, Journal of gastroenterology and hepatology.
[8] G. Niu,et al. Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis. , 2009, Molecular pharmaceutics.
[9] Zhao-You Tang,et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival , 2009, Journal of Cancer Research and Clinical Oncology.
[10] G. Qian,et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. , 2008, Journal of hepatology.
[11] S. Poppema,et al. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin‐driven sprouting neovascularization , 2008, Hepatology.
[12] N. Yaegashi,et al. Expression of vasohibin as a novel endothelium‐derived angiogenesis inhibitor in endometrial cancer , 2008, Cancer science.
[13] A. Paradiso,et al. EGFR and VEGFR as potential target for biological therapies in HCC cells. , 2008, Cancer letters.
[14] J. Goździkiewicz,et al. Angiogenesis and the progress of vascular and tumor biology: A tribute to Judah Folkman , 2008, Thrombosis and Haemostasis.
[15] G. Abou-Alfa,et al. Current management of advanced hepatocellular carcinoma. , 2008, Gastrointestinal cancer research : GCR.
[16] O. Stoeltzing,et al. Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model , 2008, Langenbeck's Archives of Surgery.
[17] Ines Gockel,et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. , 2008, Oncology reports.
[18] O. Matsui,et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. , 2007, Human pathology.
[19] S. Atkin,et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases , 2007, International journal of experimental pathology.
[20] M. Colombo,et al. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma , 2007, Journal of viral hepatitis.
[21] J. Dufour,et al. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2 , 2007, Journal of drug targeting.
[22] Konstantin V Balakin,et al. VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.
[23] 中村 功一. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1α are involved in malignant transformation in dysplastic nodules of the liver , 2007 .
[24] H. Tomita,et al. Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. , 2006, Oncology reports.
[25] J. Donckier,et al. Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin‐1 and angiogenic factors in human papillary thyroid carcinoma , 2006, Clinical endocrinology.
[26] H. Blum,et al. Hepatocellular carcinoma: therapy and prevention. , 2005, World journal of gastroenterology.
[27] Zhen-ping Zhu,et al. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. , 2005, Frontiers in bioscience : a journal and virtual library.
[28] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[29] Weiguo Lu,et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. , 2004, Gynecologic oncology.
[30] P. Kasi,et al. Improvement of water and sanitation for developing countries , 2004, The Lancet.
[31] S. Fan,et al. Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[32] Haiyang Xie,et al. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. , 2003, Hepatobiliary & pancreatic diseases international : HBPD INT.
[33] S. Ran,et al. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. , 2003, Neoplasia.
[34] S. Rafii,et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.
[35] L. Albarello,et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. , 2003, Human pathology.
[36] S. Thorgeirsson,et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.
[37] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[38] B. Wiedenmann,et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma , 2001, Gut.
[39] D. Hicklin,et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. , 2000, Oncology reports.
[40] Stanley R. Hamilton,et al. Pathology and genetics of tumours of the digestive system , 2000 .
[41] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[42] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.